Moneycontrol PRO
you are here: HomeNewsSandoz
sandoz
Jump to
13 Results Found
  • Plan to enter EU market with Insulin Glargine in second half of the year: Biocon Mar 28, 2018 03:21 PM IST

    Plan to enter EU market with Insulin Glargine in second half of the year: Biocon

    We are now ready to enter the European market with our Insulin Glargine as a biosimilar, in the second half of this year, said Kiran Mazumdar Shaw, CMD, Biocon.

  • Partnership with Sandoz is for the future wave of biosimilars: Biocon Jan 19, 2018 12:28 PM IST

    Partnership with Sandoz is for the future wave of biosimilars: Biocon

    The company is trying to combine forces with companies who have been successful in biosimilars, said Kiran Mazumdar Shaw, CMD, Biocon.

  • EU regulator recommends suspending 300 drugs tested by Indian CRO firm Mar 27, 2017 09:21 AM IST

    EU regulator recommends suspending 300 drugs tested by Indian CRO firm

    The European Medicines Agency (EMA) said that the suspension has been ordered for all drugs for which the bioequivalence studies were conducted by Micro Therapeutic Research Labs at two sites in India.

  • Starting to design clinical studies in India: Novartis Feb 10, 2017 04:28 PM IST

    Starting to design clinical studies in India: Novartis

    Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio.

  • USFDA to review Biocon-Mylan's biosimilar drug for breast cancer Jan 12, 2017 08:21 AM IST

    USFDA to review Biocon-Mylan's biosimilar drug for breast cancer

    Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.

  • Cipla Q2 profit seen up 74% on export formulation biz boost Nov 04, 2015 12:23 PM IST

    Cipla Q2 profit seen up 74% on export formulation biz boost

    Nexium (used to treat certain stomach and esophagus problem) & Pulmicort (used to prevent asthma attacks) supply may boost company's export formulation business during the quarter. Hence, export formulation business may grow around 35-40 percent year-on-year.

  • USFDA warns Novartis of violations at 2 India plants Oct 28, 2015 06:04 PM IST

    USFDA warns Novartis of violations at 2 India plants

    The warning, issued to Novartis's generic drugs unit Sandoz on Oct. 22, came after FDA officials inspected its Turbhe and Kalwa sites in western India in August 2014.

  • Cipla rises 4% on asthma drug launch, Kotak says buy Jul 30, 2015 01:10 PM IST

    Cipla rises 4% on asthma drug launch, Kotak says buy

    Kotak has a buy rating on Cipla with a target price of Rs 730 per share. Expecting launch of other two strengths (USD 600 million) in days to follow , the brokerage says Cipla will receive mark-up and profit share.

  • CCI clears Novartis-GSK pharma deal Dec 23, 2014 08:21 PM IST

    CCI clears Novartis-GSK pharma deal

    The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business, while the latter would purchase GSK's cancer drugs portfolio.

  • Ranbaxy, Sun Pharma fall 4-5%; analysts say DRL to benefit Nov 07, 2014 10:04 AM IST

    Ranbaxy, Sun Pharma fall 4-5%; analysts say DRL to benefit

    Brokerages are worried about the stocks and stress that approval of Sun Pharma-Ranbaxy deal will be key driver. They feel that this negative surprise may benefit Dr Reddy's.

  • See shared exclusivity on Copaxone generic 40mg: PLilladher Sep 01, 2014 11:38 AM IST

    See shared exclusivity on Copaxone generic 40mg: PLilladher

    According to Surajit Pal, both Natco Pharma and Dr. Reddy‘s share exclusivity and two-three more companies are also expected to join the same.

  • Sandoz files citizen petition against Ranbaxy‘s Nexium FTF Jun 27, 2012 04:45 PM IST

    Sandoz files citizen petition against Ranbaxy‘s Nexium FTF

    CNBC-TV18's Archana Shukla reports that German pharma MNC Sandoz has filed a citizen's petition against Ranbaxy asking it to forfeit its first-to-file (FTF) status for the blockbuster drug Nexium.

  • Natco loses patent case against Teva of anti-sclerosis drug Jun 25, 2012 05:14 PM IST

    Natco loses patent case against Teva of anti-sclerosis drug

    Natco Pharma Ltd has lost a patent litigation against Israel's Teva Pharmaceutical Industries Ltd in the US over multiple sclerosis treatment drug, Copaxone.

Sections
ISO 27001 - BSI Assurance Mark